Genprex Inc (GNPX) - Net Assets
Based on the latest financial reports, Genprex Inc (GNPX) has net assets worth $16.93 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.31 Million) and total liabilities ($3.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genprex Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.93 Million |
| % of Total Assets | 83.37% |
| Annual Growth Rate | 35.07% |
| 5-Year Change | -80.71% |
| 10-Year Change | 390.0% |
| Growth Volatility | 626.51 |
Genprex Inc - Net Assets Trend (2015–2025)
This chart illustrates how Genprex Inc's net assets have evolved over time, based on quarterly financial data. See how many days can Genprex Inc fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Genprex Inc (2015–2025)
The table below shows the annual net assets of Genprex Inc from 2015 to 2025. For live valuation and market cap data, see GNPX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.96 Million | +391.43% |
| 2024-12-31 | $1.62 Million | -78.15% |
| 2023-12-31 | $7.42 Million | -66.70% |
| 2022-12-31 | $22.27 Million | -46.04% |
| 2021-12-31 | $41.28 Million | +33.51% |
| 2020-12-31 | $30.92 Million | +922.52% |
| 2019-12-31 | $3.02 Million | -65.96% |
| 2018-12-31 | $8.88 Million | +1972.25% |
| 2017-12-31 | $428.57K | -73.62% |
| 2016-12-31 | $1.62 Million | +312.68% |
| 2015-12-31 | $393.74K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genprex Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16102236000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.29K | 0.04% |
| Other Components | $178.99 Million | 2248.05% |
| Total Equity | $7.96 Million | 100.00% |
Genprex Inc Competitors by Market Cap
The table below lists competitors of Genprex Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mantle Minerals Ltd
AU:MTL
|
$5.12 Million |
|
Mint Corp
V:MIT
|
$5.12 Million |
|
Sungshin Cement Co Ltd
KO:004985
|
$5.12 Million |
|
ScandiDos AB
ST:SDOS
|
$5.12 Million |
|
Aston Martin Lagonda Global Holdings PLC
LSE:AML
|
$5.11 Million |
|
Bumi Citra Permai Tbk
JK:BCIP
|
$5.11 Million |
|
Above Food Ingredients Inc. Common Stock
NASDAQ:ABVE
|
$5.11 Million |
|
BCM Alliance Bhd
KLSE:0187
|
$5.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genprex Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,620,155 to 7,961,876, a change of 6,341,721 (391.4%).
- Net loss of 16,228,953 reduced equity.
- New share issuances of 21,540,404 increased equity.
- Other factors increased equity by 1,030,270.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.23 Million | -203.83% |
| Share Issuances | $21.54 Million | +270.54% |
| Other Changes | $1.03 Million | +12.94% |
| Total Change | $- | 391.43% |
Book Value vs Market Value Analysis
This analysis compares Genprex Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $422.01 | $0.48 | x |
| 2016-12-31 | $299.96 | $0.48 | x |
| 2017-12-31 | $74.53 | $0.48 | x |
| 2018-12-31 | $0.64 | $0.48 | x |
| 2019-12-31 | $377.28 | $0.48 | x |
| 2020-12-31 | $1740.70 | $0.48 | x |
| 2021-12-31 | $1752.81 | $0.48 | x |
| 2022-12-31 | $929.00 | $0.48 | x |
| 2023-12-31 | $271.12 | $0.48 | x |
| 2024-12-31 | $20.22 | $0.48 | x |
| 2025-12-31 | $8.54 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genprex Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -203.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-203.83%) is above the historical average (-357.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -271.68% | 0.00% | 0.00x | 1.04x | $-1.11 Million |
| 2016 | -254.31% | 0.00% | 0.00x | 1.18x | $-4.29 Million |
| 2017 | -773.30% | 0.00% | 0.00x | 2.94x | $-3.36 Million |
| 2018 | -139.31% | 0.00% | 0.00x | 1.04x | $-13.26 Million |
| 2019 | -352.39% | 0.00% | 0.00x | 1.17x | $-10.96 Million |
| 2020 | -58.04% | 0.00% | 0.00x | 1.01x | $-21.03 Million |
| 2021 | -50.06% | 0.00% | 0.00x | 1.04x | $-24.79 Million |
| 2022 | -106.58% | 0.00% | 0.00x | 1.13x | $-25.97 Million |
| 2023 | -416.11% | 0.00% | 0.00x | 1.44x | $-31.60 Million |
| 2024 | -1303.03% | 0.00% | 0.00x | 2.55x | $-21.27 Million |
| 2025 | -203.83% | 0.00% | 0.00x | 1.28x | $-17.03 Million |
Industry Comparison
This section compares Genprex Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genprex Inc (GNPX) | $16.93 Million | -271.68% | 0.20x | $5.12 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Genprex Inc
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing pla… Read more